Cetuximab Plus FOLFIRI Extended Survival In Metastatic Colorectal Cancer
Dr. Tanios Bekaii-Saab, who is a HemOnc Today Editorial Board member, offered this perspective on studies presented at ASCO earlier this month: Three studies presented at ASCO suggest that an irinotecan-based backbone (FOLFIRI) remains preferred when considering combinations with biologics (VEGF or EGFR inhibitors) in metastatic colorectal cancer (mCRC). The EPOCH trial suggested harmful effects when adding cetuximab to FOLFOX vs. FOLFOX alone in resectable liver-only mCRC. FIRE3 and TRIBE showed very consistent results with FOLFIRI and bevacizumab, with superior survival compared with historical controls. Although TRIBE suggests that the triple drug regimen (FOLFOXIRI) may be superior when added to bevacizumab vs. the doublet, the absence of second-line data limits the interpretation of results.